Paul Guedeney

Showing 1-4 of 4 articles

Coronary interventions

Culprit lesion location and outcomes in patients with multi-vessel disease and infarct-related cardiogenic shock. A core laboratory analysis of the CULPRIT-SHOCK trial

Hauguel-Moreau M, Barthelemy O, Farhan s, Huber K, Rouanet S, Zeitouni M, Guedeney P, Hage G, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G

September 8, 2020 | 10.4244/EIJ-D-20-00561

Coronary interventions

Angiographic predictors of outcome in myocardial infarction patients presenting with cardiogenic shock: A CULPRIT-SHOCK angiographic substudy

Overtchouk P, Barthelemy O, Hauguel-Moreau M, Guedeney P, Rouanet S, Zeitouni M, Silvain J, Collet J-P, Vicaut E, Zeymer U, Desch S, Thiele H, Montalescot G, Bertin B, Brugier D, Vignolles N, Hage G, El Kasty M, Kerneis M, Huber K, Sandri M, Noc M, Fuernau G

July 7, 2020 | 10.4244/EIJ-D-20-00139

GLOBAL LEADERS: looking now at the bigger picture

Guedeney P, Montalescot G

December 20, 2019 | 10.4244/EIJV15I12A192

Intravenous enoxaparin anticoagulation in percutaneous left atrial cardiac procedures

Guedeney P, Hammoudi N, Duthoit G, Yan Y, Silvain J, Pousset F, Isnard R, Redheuil A, Kerneis M, Collet J-P, Montalescot G

November 20, 2017 | 10.4244/EIJ-D-17-00518

1

Latest news

Focus on emerging physiology indices, TAVI, sizing with abnormal aortic cusps, a megaregistry of complex PCIs and more…

Tetralogy of Fallot with acquired double right ventricular outflow tract

September 18, 2020

Ahead of print: Leaflex Study

September 23, 2020

Integrating physiology in OCT

September 23, 2020

BioFlow IV, TWILIGHT, Evolut Low Risk and many others

(Released thanks to the support of Biotronik)

September 25, 2020

Guidance Papers

Guidelines, consensus & position papers

August 28, 2020

Steady-state hyperaemia

September 18, 2020

This Week's JAA's: Biograde Study, Advances in valvular heart interventions...

September 22, 2020

Valvular disease